Diabetic somatic neuropathy - Pathogenesis. Clinical manifestations and therapeutical concepts;Diabetische somatische polyneuropathie

Fortschritte der Neurologie Psychiatrie

Volumn 68, Issue 6, 2000, Pages 278-288

  Hilz, M J ^a,b   Marthol, H ^a   Neundorfer B ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; CAPSAICIN; CARBAMAZEPINE; ESSENTIAL FATTY ACID; FREE RADICAL; FRUCTOSE; GABAPENTIN; GAMMA LINOLENIC ACID; INOSITOL; LAMOTRIGINE; MEXILETINE; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; PROSTANOID; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN; SORBITOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DIABETIC NEUROPATHY; ESSENTIAL FATTY ACID DEFICIENCY; FOOT AMPUTATION; GERMANY; HUMAN; HYPERGLYCEMIA; HYPOXIA; NERVE CONDUCTION; OXIDATIVE STRESS; PATHOGENESIS; RADICULOPATHY; T LYMPHOCYTE ACTIVATION; PATHOLOGY; REVIEW;

DIABETIC NEUROPATHIES; HUMANS;

EID: 0034201248     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-11535     Document Type: Article

References (145)

1. Hauner H. Verbreitung des Diabetes mellitus in Deutschland. Dtsch Med Wochenschr 1998; 123: 777-782
2. Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4400 patients observed between 1947-1973. Diabetes Care 1978(1); 168-188: 252-263
3. Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992; 6: 49-57
4. Ziegler D, Gries FA. Klassifikation, Epidemiologie, Prognose und sozialmedizinische Bedeutung. Dt Ärztebl 1996; 93(A): 680
5. Neundörfer B. Diabetische Polyneuropathie. Nervenheilkunde 1998; 17: 420-423
6. Hilz MJ, Stemper B. Staging der diabetischen Neuropathie. Nervenheilkunde 1998; 17: 424-429
7. Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824
8. Neundörfer B. Polyneuropathien: Standards. Nervenheilkunde 1995; 14: 164-174
9. Dyck PJ, Kratz KM, Lehmann KA et al. The Rochester Diabetic Neuropathy Study: Design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991; 41: 799-807
10. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599-606
11. Greene DA, Sima AF, Pfeifer MA, Albers JW. Diabetic neuropathy. Annu Rev Med 1990; 41: 303-317
12. Lee TS, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C elevated glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A 1989; 86: 5141-5145
13. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661-665
14. Williamson JR, Chang K, Frangos M et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-813
15. Cotter MA, Cameron NE. The aetiopathogenesis of diabetic neuropathy: metabolic theories. In: Boulton AJM, (ed.). Diabetic neuropathy. Carnforth: Marius Press, 1997: 97-119
16. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46: S31-37
17. Cameron NE, Cotter MA, Hohmann TC. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologica 1996; 39: 172-182
18. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
19. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci USA 1981; 78: 5190-5192
20. Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidants stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897
21. Guy RJ, Richards F, Edmonds ME, Watkins PJ. Diabetic autonomic neuropathy and iritis: an association suggesting an immunological cause. Br Med J (Clin Res Ed) 1984; 289: 343-345
22. Gilbey SG, Guy RJ, Jones H, Vergani D, Watkins PJ. Diabetes and autonomic neuropathy: an immunological association?. Diabet Med 1986; 3: 241-245
23. Gilbey SG, Hussain MJ, Watkins PJ, Vergani D. Cell-mediated immunity and symptomatic diabetic autonomic neuropathy. Diabetic Med 1988; 5: 845-848
24. Rabinowe SL. Immunology of diabetic and polyglandular neuropathy. Diabetes Metab Rev 1990; 6: 169-188
25. Muhr-Becker D, Ziegler AG, Druschky A et al. Evidence for specific autoimmunity against sympathetic and parasympathetic nervous tissues in Type 1 diabetes mellitus and the relation to cardiac autonomic dysfunction. Diabet Med 1998; 15: 467-472
26. Said G, Elgrably F, Lacroix C et al. Painful proximal diabetic neuropathy: inflammatory nerve lesions and spontaneous favorable outcome. Ann Neurol 1997; 41: 762-770
27. Younger DS, Rosoklija G, Hays AP et al. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve 1996; 19: 722-727
28. Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994; 35: 559-569
29. Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 1997; 46: S43-49
30. Vogel KS. Development of trophic interactions in the vertebrate peripheral nervous system. Mol Neurobiol 1993; 7: 363-382
31. Faradji V, Sotelo J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 1990; 81: 402-406
32. Ishii DN. Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Brain Res Rev 1995; 20: 47-67
33. Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi DV. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 1996; 2: 703-707
34. Giannini C, Dyck JP. Pathologic Alterations in Human Diabetic Polyneuropathy. In: Dyck PJ, Thomas PK, eds. Diabetic Neuropathy. 2 ed. Philadelphia: WB Saunders, 1998: 279-295
35. Fagerberg SE. Diabetic neuropathy. A clinical and histological study on the significance of vascular affections. Acta Med Scand 1959; 164: 1-99
36. Vital C, Le Blanc M, Vallat JM et al. Ultrastructural study of pheripheral nerve in 16 diabetics without neuropathy: Comparisons with 16 diabetic neuropathies and 16 non-diabetic neuropathies. Acta Neuropathol 1974; 30: 63-72
37. Bergstrand A, Bucht H. Electron microscopic investigations in the glomerular lesions in diabetic mellitus. Lab Invest 1957; 6: 293-300
38. Farquhar MG, Hopper J, Moon HD. Diabetic glomerulosclerosis: Electron and light microscopic studies. Am J Pathol 1959; 35: 721-753
39. Toussaint D, Dustin P. Electron microscopy of normal and diabetic retinal capillaries. Arch Ophthalmol 1963; 70: 96-108
40. Dachs S, Churg J, Mautner W, Grisham E. Diabetic nephropathy. Am J Pathol 1964; 44: 155-161
41. Friederici HHR, Tucker WR, Schwartz TB. Observations on small blood vessels of skin in the normal and in diabetic patients. Diabetes 1966; 15: 233-250
42. Yodaiken RE, Seftel HC, Rubenstein AN. Ultrastructure of dermal capillaries of Africans in South Africa. Diabetes 1967; 16: 191
43. Timperley WR, Boulton AJ, Davies-Jones GA, Jarratt JA, Ward JD. Small vessel disease in progressive diabetic neuropathy associated with good metabolic control. J Clin Pathol 1985; 38: 1030-1038
44. Dyck PJ, Hansen S, Karnes J et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci U S A 1985; 82: 2513-2517
45. Timperley WR, Ward JD, Preston FE, Duckworth T, O'Mally BC. Clinical and historical studies in diabetic neuropathy: A reassessment of vascular factors in relation to vascular coagulation. Diabetologia 1976; 12: 237-243
46. Malik RA, Newrick PG, Sharma AK et al. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989; 32: 92-102
47. Williams E, Timperley WR, Ward JD, Duckworth T. Electron microscopic studies of vessels in diabetic peripheral neuropathy. J Clin Pathol 1980; 33: 462-470
48. Johnson PC, Doll SC, Cromey DW. Pathogenesis of diabetic neuropathy. Ann Neurol 1986; 19: 450-457
49. Powell HC, Rosoff J, Myers RR. Microangiopathy in human diabetic neuropathy. Acta Neuropathol 1985; 68: 295-305
50. Sima AA, Nathaniel V, Prashar A, Bril V, Greene DA. Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor. Diabetes 1991; 40: 1090-1099
51. Giannini C, Dyck PJ. Ultrastructural morphometric features of human sural nerve endoneurial microvessels. J Neuropathol Exp Neurol 1993; 52: 361-369
52. Giannini C, Dyck PJ. Ultrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabetes mellitus. Ann Neurol 1994; 36: 408-415
53. Yasuda H, Dyck PJ. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 1987; 37: 20-28
54. Neundörfer B. Diabetische Polyneuropathie sicher diagnostizieren. Therapiewoche 1996; 11: 576-581
55. Neundörfer B, Claus D, Luft D. Klinik und Therapie der sensomotorischen diabetischen Polyneuropathie. Dt Ärztebl 1996; 93(A): 1529-1532
56. Thomas PK, Tomlinson FR. Diabetic and Hypoglycemic Neuropathy. In: Dyck PJ, Thomas PK, eds. Peripheral Neuropathy. Philadelphia: Saunders, 1993: 1219-1250 vol 2
57. Zorilla E, Kozak GB. Ophthalmoplegia in Diabetes mellitus. Ann Intern Med 1967; 67: 968-972
58. Schulz A. Brennende Schmerzen an Rumpf und Oberschenkel mit Bauchdeckenparesen. Dtsch Med Wochenschr 1972; 97: 1568-1569
59. Raff MC, Asbury AK. Ischemic Mononeuropathy and mononeuropathy multiplex in diabetes mellitus. New Engl J Med 1968; 279: 17-21
60. Stemper B, Hilz MJ. Autonome diabetische Neuropathie: kardiale und peripher-autonome Befunde. Nervenheilkunde 1998; 17: 437-443
61. Hilz MJ, Dütsch M, Neundörfer B. Autonome Störungen bei Polyneuropathien. Med Klin 1998; 93: 533-540
62. Ziegler D. Therapie der peripheren diabetischen Neuropathie. Diab Stoffw 1998; 7: 103-113
63. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-568
64. Amthor KF, Dahl-Jorgensen K, Berg TJ et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1994; 37: 579-584
65. Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996; 39: 1483-1488
66. Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care 1997; 20: 1594-1597
67. Ziegler D, Dannehl K, Wiefels K, Gries FA. Differential effects of near-normoglycaemia for 4 years on somatic nerve dysfunction and heart rate variation in type 1 diabetic patients. Diabet Med 1992; 9: 622-629
68. Ziegler D. Diagnostik und Therapie der diabetischen Neuropathie. Ther Umsch 1996; 53: 948-957
69. Hilsted J, Low PA. Diabetic Autonomic Neuropathy. In: Low PA, ed. Clinical Autonomic Disorders. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1997: 487-507
70. Thomas PK. Mechanisms and Treatment of Pain. In: Dyck PJ, Thomas PK, eds. Diabetic Neuropathy. 2 ed. Philadelphia: W.B. Saunders Company, 1998: 387-397
71. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
72. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1999; 22: S32-S42
73. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care 1993; 16: 1517-1520
74. American Diabetes Association. Nutritional recommendations and principles for individuals with diabetes mellitus: 1986. Diabetes Care 1987; 10: 126-132
75. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 179-182
76. Weir GC, Nathan DM, Singer DE. Standards of care for diabetes. Diabetes Care 1994; 17: 1514-1522
77. Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994; 10: 189-224
78. Low PA, Nickander KK, Scionti L Role of Hypoxia, Oxidative Stress, and Excitatory Neurotoxins in Diabetic Neuropathy. In: Dyck PJ, Thomas PK, eds. Diabetic Neuropathy. 2 ed. Philadelphia: W. B. Saunders Company, 1998: 317-329
79. Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19: 227-250
80. Busse E, Zimmer G, Schopohl B, Kornhuber B. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung 1992; 42: 829-831
81. Murase K, Hattori A, Kohno M, Hayashi K. Stimulation of nerve growth factor synthesis/secretion in mouse astroglial cells by coenzymes. Biochem Mol Biol Int 1993; 30: 615-621
82. Dimpfel W, Spuler M, Pierau FK, Ulrich H. Thioctic acid induces dose-dependent sprouting of neurites in cultured rat neuroblastoma cells. Dev Pharmacol Ther 1990; 14: 193-199
83. Nagamatsu M, Nickander KK, Schmelzer JD et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy Diabetes Care 1995; 18: 1160-1167
84. Ziegler D, Hanefeld M, Ruhnau KJ et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic: acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-1433
85. Ziegler D, Schatz H, Conrad F et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997; 20: 369-373
86. Reljanovic M, Reichel G, Rett K et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res Sep 1999; 31: 171-179
87. Ziegler D, Hanefeld M, Ruhnau KJ et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study) ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care Aug 1999; 22: 1296-1301
88. Tomlinson DR. Role of Aldose Reductase Inhibitors in the Treatment of Diabetic Polyneuropathy. In: Dyck PJ, Thomas PK, eds. Diabetic Neuropathy. 2 ed. Philadelphia: W. B. Saunders Company, 1998: 330-340
89. Dvornik E, Simard-Duquesne N, Krami M et al. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science 1973; 182: 1146-1148
90. Greene DA, De Jesus PV Jr., Winegrad AI. Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 1975; 55: 1326-1336
91. Arendrup K, Gregersen G, Hawley J, Hawthorne JN. High-dose dietary myo-inositol supplementation does not alter the ischaemia phenomenon in human diabetics. Acta Neurol Scand 1989; 80: 99-102
92. Julu POO. Essential fatty acids prevent slowed nerve conduction velocity in streptozotocin diabetic rats. J Diabetes Complications 1988; 2: 185
93. Cameron NE, Cotter MA. Role of Linolenic Acid in Diabetic Polyneuropathy. In: Dyck PJ, Thomas PK, eds. Diabetic Neuropathy. 2 ed. Philadelphia: W. B. Saunders, 1998: 359-367
94. Holman RT, Johnson SB, Gerrard JM et al. Arachidonic acid deficiency in streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1983; 80: 2375-2379
95. Greene DA, Sima AAF, Stevens MJ. Complications: Neuropathy, pathogenetic considerations. Diabetes Care 1992; 15: 1902
96. Apfel SC, Kessler JA, Adornato BT et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998; 51: 695-702
97. Hayakawa K, Sobue G, Itoh T, Mitsuma T. Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion expiants in vitro. Life Sci 1994; 55: 519-529
98. Apfel SC, Kessler JA. Neurotrophic factors in the treatment of peripheral neuropathy. Ciba Found Symp 1996; 196: 98-108
99. Levi-Montalcini R. The nerve growth factor-target cells interaction: a model system for the study of directed axonal growth and regeneration. In: Huner B, Perez-Polo JR, Hashim GA, Stella AM, eds. Nervous system regeneration. Proceedings of an International Symposium, Satellite Meetings of International Society for Neurochemistry. Catania, Italy. New York: Alan R. Liss, Inc., 1983
100. Campenot RB. Development of sympathetic neurons in compartmentalized cultures. I1 Local control of neurite growth by nerve growth factor. Dev Biol 1982; 93: 1-12
101. Hoyle GW, Mercer EH, Palmiter RD, Brinster RL. Expression of NGF in sympathetic neurons leads to excessive axon outgrowth from ganglia but decreased terminal innervation within tissues. Neuron 1993; 10: 1019-1034
102. Zettler C, Head RJ, Rush RA. Chronic nerve growth factor treatment of normotensive rats. Brain Res 1991; 538: 251-262
103. Diamond J, Coughlin M, Macintyre L et al. Evidence that endogenous beta nerve growth factor is responsible for the collateral sprouting, but not the regeneration, of nociceptive axons in adult rats. Proc Natl Acad Sci USA 1987; 84: 6596-6600
104. Snider WD. Nerve growth factor enhances dendritic arborization of sympathetic ganglion cells in developing mammals. J Neurosci 1988; 8: 2628-2634
105. Kessler JA, Black IB. The effects of nerve growth factor (NGF) and antiserum to NGF on the development of embryonic sympathetic neurons in vivo. Brain Res 1980; 189: 157-168
106. Kessler JA, Black IB. Nerve growth factor stimulates the development of substance P in sensory ganglia. Proc Natl Acad Sci U S A 1980; 77: 649-652
107. Kessler JA, Black IB. Similarities in development of substance P and somatostatin in peripheral sensory neurons: effects of capsaicin and nerve growth factor. Proc Natl Acid Sci U S A 1981; 78: 4644-4647
108. Lindsay RM, Harmar AJ. Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature 1989; 337: 362-364
109. Thoenen H, Angeletti PU, Levi-Montalcini R, Kettler R. Selective induction by nerve growth factor of tyrosine hydroxylase and dopamine- -hydroxylase in the rat superior cervical ganglia. Proc Natl Acad Sci USA 1971; 68: 1598-1602
110. Bradshaw RA. Nerve growth factor. Annu Rev Biochem 1978; 47: 191-216
111. Thoenen H, Barde YA. Physiology of nerve growth factor. Physiol Rev 1980; 60: 1284-1335
112. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987; 237: 1154-1162
113. Rush RA, Mayo R, Zettler C. The regulation of nerve growth factor synthesis and delivery to peripheral neurons. Pharmacol Ther 1995; 65: 93-123
114. Campenot RB. NGF and the local control of nerve terminal growth. J Neurobiol 1994; 25: 599-611
115. Degenhardt TP, Fu MX, Voss E et al. Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats. Diabetes Res Clin Pract 1999; 43: 81-89
116. Piercy V, Toseland CD, Turner NC. Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice. Metabolism 1998; 47: 1477-1480
117. Friedman EA, Distant DA, Fleishhacker JF, Boyd TA, Cartwright K. Aminoguanidine prolongs survival in azotemic-induced diabetic rats. Am J Kidney Dis 1997; 30: 253-259
118. Chibber R, Molinatti PA, WongJS et al. The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes 1994; 43: 758-763
119. Cohen SM, Mathews T. Pentoxifylline in the treatment of distal diabetic neuropathy. Angiology 1991; 42: 741-746
120. Zeigler D, Lynch SA, Muir J. Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 1992; 43: 403-408
121. Neundörfer B. Neuropathic Pain - Especially in Polyneuropathies. Neurology, Psychiatry and Brain Res 1996; 4: 129-134
122. Gomez-Perez FJ, Rull JA, Dies H, Rodriquez-Rivera JG, Gonzalez-Barranco J, Lozano-Castaneda O. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain 1985; 23: 395-400
123. Max MB, Culnane M, Schafer SC et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589-596
124. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-1256
125. Sindrup SH, Bjerre U, Dejgaard A et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547-552
126. Botney M, Fields HL. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann Neurol 1983; 13: 160-164
127. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia 1993; 48: 281-285
128. McQuay HJ, Moore RA. Antidepressants and chronic pain. Bmj 1997; 314: 763-764
129. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anti-convulsant drugs for management of pain: a systematic review. Bmj 1995; 311: 1047-1052
130. Galer BS. Neuropathic pain of peripheral origin: Advances in pharmacologic treatment. Neurology 1996; 45: S17
131. Backonja M, Beydoun A, Edwards KR et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998 Dec 2; 280: 1831-1836
132. Harbison J, Dennehy F, Keating D. Lamotrigine for pain with hyperalgesia. Ir Med J 1997; 90: 56
133. McQuay HJ. Opioid use in chronic pain. Acta Anaesthesiol Scand 1997; 41: 175-183
134. Harati Y, Gooch C, Swenson M et al. The TPSDN study group: A double-blind placebo-controlled trial of tramadol for the pain of diabetic peripheral neuropathy. J Peripher Nerv Syst 1997; 2: 270
135. Schaumburg H, Kaplan J, Windebank A et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983; 309: 445-448
136. Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmacol Ther 1996; 34: 47-50
137. Haupt E, Ledermann H, Köpeke W. Benfotiamine on treatment of diabetic polyneuropathy. J Peripher Nerv Syst 1997; 2: 270
138. Gallai V, Mazzotta G, Montesi S, Sarchielli P, Del Gatto F. Effects of uridine in the treatment of diabetic neuropathy: an electrophysiological study. Acta Neurol Scand 1992; 86: 3-7
139. Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1987; 147: 1442-1444
140. van der Sloot P, Mizisin A, Zochodne D. Sulindac in established experimental diabetes: a follow-up study. Can J Neurol Sci 1995; 22: 198-201
141. Forst T, Pfützner A, Ayric H, Ambrosch A, Lehnert H, Küstner E. Die transkutane elektrische Nervenstimulation in der Therapie der symptomatischen somatosensorischen diabetischen Polyneuropathie. Diab Stoffw 1996; 5: 203-208
142. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995; 52: 1053-1061
143. Krendel DA. Immunotherapy of neuropathies in patients with diabetes mellitus requires closer scrutiny (in reply). Arch Neurol 1996; 53: 591-592
144. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol 1996; 55: 1181-1193
145. Masuhr KF, Neumann M. Neurologie. Stuttgart: Hippokrates-Verl., 1989